LXRX
LEXICON PHARMACEUTICALS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 23 to Feb 25 ▲ 2 days of insider buys: $150.0K by 1 insider, avg $1.47
- Mar 5 ▲ Lexicon Pharmaceuticals reported Q4 2025 financial results with $5.5…
- Mar 5 Lexicon Pharmaceuticals reported Q4 and full-year 2025 financial res…
- Mar 23 ▲ Lexicon Pharmaceuticals announced that Novo Nordisk has initiated a…
- Mar 24 Lexicon Pharmaceuticals presented new clinical data for sotagliflozi…
- Apr 22 HSR Early Termination: Stichting Administratiekantoor…
- Apr 30 ▼ Lexicon Pharmaceuticals filed an 8-K reporting the automatic convers…
- Sep 28 Cantor Fitzgerald initiates
- Oct 19 Trial readout: T-90d Trial Readout: Sotagliflozin (Phase 3)
- Oct 26 Trial readout: T-90d Trial Readout: Sotagliflozin (Phase 3)
- Nov 5 ▲ Earnings: LXRX Q3 2026 Earnings: EPS $-0.03 (+49.4% vs est)
- Nov 6 ▲ 1 insider buy $50.0K at $1.66
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $200.0K at an average $1.51. No open-market sales. Price is 16% above their cost.
- InstitutionsBULLISH
Q3 2026: 19 added (0 new), 11 trimmed or exited.
- AnalystsBULLISH
9 of 12 rate it Buy or better. Median target $4.70 (+169%).
- EstimatesFALLING
Current-quarter EPS estimate −$0.036 → −$0.054 over 90 days.
- Short sellersSTEADY
Short interest −3.1% to 25.88M shares. 14.0 days to cover, ≈5.8% of shares.
- TrendRANGE
1% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $125.1M |
| STATE STREET CORP | ADD | $14.0M |
| UBS Group AG | DOUBLED | $3.4M |
| Squarepoint Ops LLC | DOUBLED | $939.7K |
| MORGAN STANLEY | ADD | $377.9K |
| BARCLAYS PLC | NEAR_EXIT | $174.7K |
| Quadrature Capital Ltd | DOUBLED | $149.2K |
| GROUP ONE TRADING LLC | TRIM | $114.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is inside the target range. Median implies +169%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | Citigroup MAINTAIN | Buy |
| Sep 28, 2026 | Cantor Fitzgerald INITIATE | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Exton Michael Chief Executive Officer Nov 6, 2026 | BUY | $50.0K |
DEBBANE RAYMOND Director Jun 3, 2026 | EXERCISE | 89,312 sh |
BARKER SAM L Director Jun 3, 2026 | EXERCISE | 89,312 sh |
Amouyal Philippe Director Jun 3, 2026 | EXERCISE | 89,312 sh |
Cheung Ivan Director Jun 3, 2026 | EXERCISE | 89,312 sh |
Sullivan Diane E. Director Jun 3, 2026 | EXERCISE | 89,312 sh |
SOBECKI CHRISTOPHER J Director Jun 3, 2026 | EXERCISE | 89,312 sh |
Swain Judith L Director Jun 3, 2026 | EXERCISE | 89,312 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.05 | -$0.06–-$0.03 | -50.3% | $4.3M |
| Next Q | -$0.06 | -$0.06–-$0.06 | -20.0% | $603.3K |
| Current FY | -$0.16 | -$0.17–-$0.14 | +4.5% | $37.4M |
| Next FY | -$0.21 | -$0.27–-$0.11 | -11.7% | $17.9M |
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 3 press releases · 1 bullish · 3 bearish · 9 neutral- NEUTRAL SC 13G/ANov 5, 2026
Fidelity (FMR LLC) filed an amended Schedule 13G reporting beneficial ownership of 66,743,389.66…
Fidelity's passive stake remains stable at 15%, with a negligible increase of ~4,100 shares since the prior filing. No signal of activist intent. Monitor whether Fidelity converts to a 13D filing if…
- NEUTRAL 8-KNov 5, 2026
Lexicon reported Q3 2026 total revenue of $11.3M, down from $14.2M a year ago, driven by lower…
Monitor SONATA-HCM top-line results in Q1 2027 and the ZYNQUISTA NDA resubmission timeline; the cash runway of $183M supports operations into 2027 without near-term financing.
- NEUTRAL PRESS-RELEASENov 5, 2026
Lexicon reported Q3 2026 net loss of $0.03 per share, narrower than the consensus estimate of…
The EPS and revenue beats are largely non-recurring (milestone-driven). Focus shifts to Q1 2027 catalysts: SONATA-HCM topline and ZYNQUISTA NDA resubmission. Cash runway appears sufficient through…
- BEARISH INST-CLUSTERSep 22, 2026
A mixed institutional cluster in LXRX shows 14 buyers adding $60.6M in new positions (dominated by…
The divergence between passive buying (BlackRock, Geode, Vanguard) and active quant selling (Millennium, Susquehanna, RenTech) is a cautionary signal. Monitor upcoming 13F filings for further…
All LXRX filing & press-release reports (16)
- SC 13G/A reportNov 5, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- INST-CLUSTER reportSep 22, 2026
- PRESS-RELEASE reportAug 6, 2026
- 8-K reportAug 6, 2026
- INST-CLUSTER reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 6, 2026
- 8-K reportApr 30, 2026
- PRESS-RELEASE reportApr 30, 2026
- PRESS-RELEASE reportMar 24, 2026
- PRESS-RELEASE reportMar 23, 2026
- DEFA14A reportMar 16, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026